Biktarvy’s current market pricing and official selling price

Biktarvy, also known as Biktarvy, is a first-line antiviral compound preparation for the treatment of HIV infection. It contains three active ingredients: biktinol, emtricitabine and tenofovir alafenamide. With its high efficiency, safety, convenience and other characteristics, Bituvi is widely used around the world and has received good clinical feedback. At present, Bituvi has been officially launched in China and has been successfully included in medical insurance, which has greatly reduced the financial burden of patients.

In the domestic market, the original version of Bituvit is produced by Gilead. Each box contains 30 capsules, which is a one-month treatment cycle. According to the latest pharmacy quotation, the price after medical insurance reimbursement is about more than a thousand yuan, which has dropped significantly compared with the previous import price of several thousand yuan. This is undoubtedly a positive development for HIV patients who need medication for a long time, improving the accessibility and compliance of medications.

In addition to the domestically marketed version, there is also a generic version of Bituvir approved for marketing in India. The ingredients of the drug are basically the same as the original drug. It also contains three ingredients: bicitinol, emtricitabine and tenofovir alafenamide. These generic drugs are produced by large Indian pharmaceutical companies such as Hetero, Mylan, etc. They comply with international drug quality standards and are widely used in many countries. The price advantage of the Indian version of generic drugs is obvious. Each box of 30 pills only costs a few hundred yuan. It is a cost-effective alternative for patients with limited financial conditions.

Taken together, whether you choose to purchase original drugs reimbursed by medical insurance in China or purchase Indian generic drugs through formal channels, the current treatment costs of Bituvet have been significantly reduced. This price controllability not only relieves patients' financial pressure, but also helps improve the popularity and sustainability of HIV antiviral treatment. As anti-HIV drugs continue to be optimized and popularized globally, highly effective drugs like Bitovil will continue to provide patients with more stable and affordable treatment options.

Reference materials:https://www.biktarvy.com/